Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)

Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)

[at noodls] – CARMIEL, Israel, Dec. 6, 2012 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has entered into a Clinical Development Agreement with Pfizer Inc. under … more

View todays social media effects on PLX

View the latest stocks trending across Twitter. Click to view dashboard

See who Protalix is hiring next, click here to view

Share this post

Comments (0)